Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918033 | 0.88 | ALOX5 (0.79) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL245269 | 0.88 | ALOX5 (0.79) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL3371697 | 0.88 | ALOX5 (0.79) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL3537588 | 0.88 | MEN1 (1.00) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL20256058 | 0.87 | ALOX5 (1.00) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL31485746 | 0.87 | MEN1 (1.00) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL3541369 | 0.86 | ALOX5 (0.76) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL10903339 | 0.86 | MEN1 (0.78) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL6118915 | 0.85 | ALOX5 (0.74) | ALOX5MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL2299414 | 0.84 | ALOX5 (0.72) | ALOX5MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551183-B1 | INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2025-08-20 | — | — | EP | disclosed |
| US-11384071-B2 | Inhibitors of mechanotransduction to treat pain and modulate touch perception | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-07-12 | — | — | US | disclosed |
| US-11384071-B2 | Inhibitors of mechanotransduction to treat pain and modulate touch perception | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-07-12 | — | — | US | disclosed |
| EP-3551183-A1 | INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2019-10-16 | — | — | EP | disclosed |
| EP-2744342-B1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10238678-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2018104479-A1 | INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018104479-A1 | INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-06-14 | — | — | WO | disclosed |
| EP-3199531-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9682999-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-8927593-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140212384-A1 | Therapeutic Methods | GLAXOSMITHKLINE LLC | 2014-07-31 | — | — | US | disclosed |
| EP-2744332-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| EP-2744342-A1 | THERAPEUTIC METHODS | GlaxoSmithKline LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2013028371-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | GLAXO GROUP LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013025992-A1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011103063-A1 | THERAPEUTIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | ALOX5 1161/4885MEN1 4450/4885KMT2A 3110/4885 |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | ALOX5 1161/4885MEN1 4450/4885KMT2A 3110/4885 |
| US-10238678-B2 | Therapeutic methods | HAVCR2, SLC10A1, OAT | ALOX5 1534/4885MEN1 4207/4885KMT2A 4626/4885 |
| US-20140212384-A1 | Therapeutic Methods | HAVCR2, SLC10A1, OAT | ALOX5 1534/4885MEN1 4207/4885KMT2A 4626/4885 |
| US-11384071-B2 | Inhibitors of mechanotransduction to treat pain and modulate touch perception | TRPA1, TRPV1, TRPV2 | ALOX5 1866/4885MEN1 4523/4885KMT2A 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.